BioMed Realty Trust Coverage Initiated by Analysts at MLV & Co (BMR)
Equities research analysts at MLV & Co
began coverage on shares of BioMed Realty Trust (NYSE:BMR) in a research note issued to investors on Friday, TheFlyOnTheWall.com reports. The firm set a “hold” rating and a $23.00 price target on the stock. MLV & Co
‘s target price indicates a potential upside of 6.28% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Robert W. Baird raised their price target on shares of BioMed Realty Trust from $22.00 to $23.00 in a research note on Tuesday, May 13th. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of BioMed Realty Trust in a research note on Thursday, April 17th. They now have a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $23.00.
BioMed Realty Trust (NYSE:BMR) traded up 0.83% on Friday, hitting $21.82. 533,285 shares of the company’s stock traded hands. BioMed Realty Trust has a 1-year low of $17.90 and a 1-year high of $22.47. The stock has a 50-day moving average of $21.70 and a 200-day moving average of $20.22. The company has a market cap of $4.166 billion and a price-to-earnings ratio of 87.97.
BioMed Realty Trust (NYSE:BMR) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.38 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.35 by $0.03. Analysts expect that BioMed Realty Trust will post $1.50 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, July 15th. Stockholders of record on Monday, June 30th will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 4.62%. The ex-dividend date is Thursday, June 26th.
BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.